Should you buy Sanofi stock now?
No, the technical signal for Sanofi is currently SELL. Sanofi trades at $42.83 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.066 with falling momentum (signal: 0.096); RSI is at 45.4 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $54.06 points to 26.2% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Sanofi stock?
The average analyst price target for Sanofi is $54.06. The current price is $42.83, which gives an upside of 26.2%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $48.65 and $59.47.
Is Sanofi a dividend stock?
Yes, Sanofi is a dividend stock with a dividend yield of 9.59%. The latest dividend was $2.42 per share. The latest ex-dividend date (traded without the dividend) was 5/4/2026. The payout ratio is 49.3%, which is considered sustainable. The next dividend payment is scheduled for 6/3/2026.
When does Sanofi pay a dividend in 2026?
Sanofi pays its next dividend on 6/3/2026. The latest dividend was $2.42 per share with an ex-dividend date of 5/4/2026. The dividend yield is 9.59%. The payout ratio of 49.3% points to a sustainable dividend with room to grow.
What is the risk of Sanofi stock?
Sanofi is rated as a stock with moderately low risk. the annual standard deviation is 25.3%, which classifies the stock as moderately low risk.
Is Sanofi overvalued?
No, Sanofi is considered undervalued based on the analyst price target (26.2% upside). Sanofi has the following valuation ratios: a P/E ratio of 22.9 (moderately to highly valued), a P/S ratio of 2.1, a P/B ratio of 1.3. The analyst price target suggests that the stock is undervalued by 26.2%.
Is Sanofi overbought?
No, Sanofi is not overbought. RSI is at 45.4 (neutral zone). The technical indicators show: RSI is at 45.4 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 2.0% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Sanofi earnings report?
The date of the next earnings report for Sanofi has not been published yet. Check the company's investor calendar for updates.
Is Sanofi shorted?
Sanofi has minimal short interest of 0.35% of the free float, which is insignificant and points to very limited bearish sentiment.
Are insiders buying Sanofi stock?
No, insiders are not buying Sanofi shares – they are net sellers. Across the last 20 reported transactions, the split is 12 purchases and 8 sales, with a net 8,824,355,495 $ sold. Active sellers include Sanofi. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Sanofi a good stock?
Based on our total score, Sanofi is rated as a good stock with a total score of 64 out of 100. The stock scores above average on value, quality and momentum – it is among the top 36% in our database. The score is made up of Value: 70/100, Quality: 69/100, Momentum: 52/100. In addition: analysts see 26.2% upside to the price target; a dividend of 9.59%; technical signal: Strong Sell. Whether Sanofi is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Sanofi stock?
The outlook for Sanofi based on current data: the average analyst price target is $54.06 (+26.2%); the stock is in a downtrend (below SMA50 and SMA200); the P/E ratio is 22.9 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Sanofi stock falling?
Sanofi is falling right now. The technical indicators show: the price is 2.0% below the 20-day average; MACD is negative with falling momentum (bearish signal); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Sanofi go?
The average analyst price target for Sanofi is $54.06, which corresponds to a potential gain of 26.2% from the current price of $42.83. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Sanofi fall?
We lack enough history to give a specific floor for Sanofi. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Sanofi do?
Sanofi er et globalt sundhedsfirma, der udvikler, producerer og sælger medicin. De tjener primært penge på terapeutiske løsninger inden for områder som immunologi, sjældne sygdomme og kræftbehandling. Virksomheden laver også vacciner, og her er de især kendt for deres børnevac... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - General industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Sanofi as an investment.
Did Sanofi raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Sanofi. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Sanofi making money or losing money?
Yes, Sanofi is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 8.1% — which is moderate. The operating margin (profit before interest and taxes) is 21.0%. At a P/E ratio of 22.9, you currently pay 22.9 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Sanofi go bankrupt?
The bankruptcy risk of Sanofi is rated as moderate. Altman Z2 (a model for assessing financial distress) is 1.66 — that places the company in the middle zone. The Piotroski score (financial health 0-9, higher is better) is 7 — which is strong. Debt relative to equity is 71% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Sanofi have a lot of debt?
No, Sanofi has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 71%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Sanofi service its debt? Can service its debt, but it weighs on the company — the interest coverage ratio (how many times earnings can cover interest payments) is 3.9x, and net debt equals 1.3 years of earnings (EBITDA).
